CANCER:

Malignant Pleural Mesothelioma

Related cancers:

‹

›

No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	cisplatin + pemetrexed Sensitive: A1 - Approval FDA - 2 days (NewA1)	cisplatin + pemetrexed Sensitive: A1 - Approval FDA - 2 days - (New A1)
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	pemetrexed Sensitive: A1 - Approval	pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	carboplatin + pemetrexed Sensitive: A2 - Guideline	carboplatin + pemetrexed Sensitive: A2 - Guideline
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	nivolumab Sensitive: A2 - Guideline	nivolumab Sensitive: A2 - Guideline
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	bevacizumab Sensitive: A2 - Guideline	bevacizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	carboplatin + raltitrexed Sensitive: A2 - Guideline	carboplatin + raltitrexed Sensitive: A2 - Guideline
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	GC Sensitive: A2 - Guideline	GC Sensitive: A2 - Guideline
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	gemcitabine Sensitive: A2 - Guideline	gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	vinorelbine tartrate Sensitive: A2 - Guideline	vinorelbine tartrate Sensitive: A2 - Guideline
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	ramucirumab Sensitive: A2 - Guideline	ramucirumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	PD-L1 expression PD-L1 expression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	nivolumab Sensitive: C1 - Off-label	nivolumab Sensitive: C1 - Off-label
WT1 expression WT1 expression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	WT1 expression WT1 expression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	nivolumab + galinpepimut-S Sensitive: C3 – Early Trials	nivolumab + galinpepimut-S Sensitive: C3 – Early Trials
TMB-L TMB-L	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	TMB-L TMB-L	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	PD1 inhibitor Resistant: C3 – Early Trials	PD1 inhibitor Resistant: C3 – Early Trials
TMB-L TMB-L	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	TMB-L TMB-L	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	PD-L1 inhibitor Resistant: C3 – Early Trials	PD-L1 inhibitor Resistant: C3 – Early Trials
PD-L1 underexpression PD-L1 underexpression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	PD-L1 underexpression PD-L1 underexpression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	PD1 inhibitor Resistant: C3 – Early Trials	PD1 inhibitor Resistant: C3 – Early Trials
ERCC1 expression ERCC1 expression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	ERCC1 expression ERCC1 expression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	GC Sensitive: C3 – Early Trials	GC Sensitive: C3 – Early Trials
RRM1 expression RRM1 expression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	RRM1 expression RRM1 expression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	GC Sensitive: C3 – Early Trials	GC Sensitive: C3 – Early Trials
MSLN overexpression MSLN overexpression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	MSLN overexpression MSLN overexpression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	TC-210 Sensitive: C3 – Early Trials	TC-210 Sensitive: C3 – Early Trials
ASS1 mutation ASS1 mutation	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	ASS1 mutation ASS1 mutation	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	cisplatin + pemetrexed + pegargiminase Sensitive: C3 – Early Trials	cisplatin + pemetrexed + pegargiminase Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	PD-L1 overexpression PD-L1 overexpression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	nivolumab Sensitive: C4 – Case Studies	nivolumab Sensitive: C4 – Case Studies
EML4-ALK I1171N + EML4-ALK L1196M EML4-ALK I1171N + EML4-ALK L1196M	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	EML4-ALK I1171N + EML4-ALK L1196M EML4-ALK I1171N + EML4-ALK L1196M	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	alectinib Resistant: C4 – Case Studies	alectinib Resistant: C4 – Case Studies

Malignant Pleural Mesothelioma

Associations(23)

Associations
(23)